23 Spam-Free Article(s) Found
Article Searches
4 Reasons Biotech Stocks Are a Buy Right Now https://www.fool.com/investing/2020/03/25/4-reasons-biotech-stocks-are-a-buy-right-now.aspx?source=iedfolrf0000001 Mar 25, 2020 - Biotech companies have outperformed the general market -- and there are plenty of reasons to remain optimistic.
Incyte to Evaluate Lead Drug Jakafi for COVID-19 Infection http://www.zacks.com/stock/news/852806/incyte-to-evaluate-lead-drug-jakafi-for-covid-19-infection?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-852806 Apr 03, 2020 - Incyte (INCY) plans to work with the FDA for evaluating Jakafi in patients with COVID-19-associated cytokine storm.
Biotech Stock Roundup: AMGN & INCY Focus on Coronavirus Treatments, & More http://www.zacks.com/stock/news/860777/biotech-stock-roundup-amgn-incy-focus-on-coronavirus-treatments-more?cid=CS-ZC-FT-analyst_blog|stock_roundup-860777 Apr 08, 2020 - The biotech sector is in focus with pipeline updates from companies evaluating treatments for the novel COVID-19.
Merck's Keytruda Gets FDA's Priority Review for Solid Tumors http://www.zacks.com/stock/news/861111/mercks-keytruda-gets-fdas-priority-review-for-solid-tumors?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-861111 Apr 08, 2020 - Merck's (MRK) sBLA seeking approval of Keytruda for advanced solid tumors, based on biomarker, regardless of tumor type, gets FDA's priority review.
6 Recession-Proof Picks Amid Coronavirus-Led "The Great Lockdown" http://www.zacks.com/stock/news/872034/6-recession-proof-picks-amid-coronavirus-led-the-great-lockdown?cid=CS-ZC-FT-analyst_blog|investment_ideas-872034 Apr 15, 2020 - Coronavirus outbreak-induced global lockdowns are making recession inevitable. Here are six recession-resistant stocks including Netflix (NFLX) to beat COVID-19 induced recession woes.
4 GARP Stocks to Scoop Up for Maximum Returns http://www.zacks.com/stock/news/872211/4-garp-stocks-to-scoop-up-for-maximum-returns?cid=CS-ZC-FT-analyst_blog|rw-872211 Apr 15, 2020 - If you're looking for a profitable portfolio of stocks that will offer the best of value and growth investing, try the growth at a reasonable price or GARP strategy.
Powerful Proof Anyone Can Invest for an Early Retirement - April 17, 2020 http://www.zacks.com/stock/news/875973/powerful-proof-anyone-can-invest-for-an-early-retirement-april-17-2020?cid=CS-ZC-FT-retirement_ideas|secrets_to_an_early_retirement-875973 Apr 17, 2020 - Accomplishing the financial cushion to retire early is a fantasy for most, but bringing that fantasy to reality is not as difficult as it sounds. If you are willing to make some serious lifestyle adjustments, it can be achievable.
Is a Beat in Store for Amarin (AMRN) This Earnings Season? http://www.zacks.com/stock/news/898431/is-a-beat-in-store-for-amarin-amrn-this-earnings-season?cid=CS-ZC-FT-analyst_blog|earnings_preview-898431 Apr 29, 2020 - Amarin's (AMRN) first-quarter results are likely to reflect strong demand for its cardiovascular drug, Vascepa.
Amgen Inc. (AMGN) CEO Bob Bradway on Q1 2020 Results - Earnings Call Transcript https://seekingalpha.com/article/4341844-amgen-inc-amgn-ceo-bob-bradway-on-q1-2020-results-earnings-call-transcript?source=feed_sector_healthcare May 01, 2020 - Amgen Inc. (NASDAQ:AMGN) Q1 2020 Earnings Conference Call April 30, 2020 5:30 PM ET Company Participants Arvind Sood - Vice President of Investor Relations Bob Bradway - Chief Executive Officer Dave R
Amgen (AMGN) Q1 Earnings Top, to Study Otezla for Coronavirus http://www.zacks.com/stock/news/910436/amgen-amgn-q1-earnings-top-to-study-otezla-for-coronavirus?cid=CS-ZC-FT-analyst_blog|earnings_article-910436 May 01, 2020 - Amgen (AMGN) beats estimates for both earnings and sales. It maintains its previously-issued financial guidance for 2020.

Pages: 123

Page 1>